Tocilizumab (Acterma) is an immunosuppressive drug (IL-6 inhibitor) mainly used in the treatment of rheumatoid arthritis and is currently being tested in COVID-19 patients. Explore the live graph.
Mechanistic analysis of Tocilizumab
RAS
Mechanistic analysis of Azithromycin
Azithromycin is being tested in COVID-19 patients. Although it is a potent antibiotic, in the COVID-19 setting, it likely acts as an anti-inflammatory agent. Its exact MoA in the disease, however, remains to be elucidated. Explore the live graph.
Administration of vitamin D could help fight COVID-19
Vitamin D supplementation has been shown to protect against SARS-COV-2 infection, and could be particularly helpful for patients that exhibit shortage of vitamin D (e.g. seniors, immunocompromised patients) leading to complications such as cardiovascular comorbidities. This graph explains the mechanism of action of vitamin D in COVID-19 via key genes implicated. Explore the live graph.
Possibly implicated genes in SARS-CoV-2-mediated blood vessel disease
In addition to respiratory symptoms, novel findings have shown vascular complications in a series of patients with COVID-19, suggesting that COVID-19 is more to a respiratory infection caused by SARS-CoV-2. This graph illustrates some of the possible mechanisms (genes) by which these effects of SARS-CoV-2 may be mediated. Explore the live graph.